Figure 1.

The use of precision oncology for the determination of potentially actionable genes with directed targeted therapy (a sequence from mass gene exploration until NTRK identification). Despite the cost of the generalized implementation of in-depth genomics, the directed use of state-of-the-art therapeutic strategies has demonstrated a global saving of 5.6% in the participating population. This care strategy based on value could reduce the global costs of directed oncological treatment after 18 months of intervention in more than 7.5%, a valid event for one in four patients with advanced cancer.¹³